Picture supply: Getty Photos
It has been a troublesome few years for FTSE 250 agency Victrex (LSE: VCT).
The polymers specialist has seen its share value fall by 27% in a single yr. Over 5 years, the decline has been 58%.
The factor is, I believe Victrex has lots to love about it as a enterprise.
If that turns into clearer once more this yr, allaying some Metropolis fears about dangers the enterprise faces, I believe the FTSE 250 share may advantage a better value.
To begin, I’ll clarify what I like about Victrex (and why I’m a shareholder in it).
A Warren Buffett-like moat
The primary purpose I like Victrex is that it has the kind of enterprise “moat” billionaire Warren Buffett usually enthuses about.
It makes excessive efficiency polymers which might be utilized in all types of functions the place security is essential, from aerospace to vehicles. That implies that high quality is a paramount consideration for patrons, giving suppliers pricing energy.
On prime of that, Victrex makes a lot of proprietary polymer merchandise that successfully imply it’s the solely selection for patrons with sure particular wants. Once more, that offers it pricing energy.
In flip, that has helped the corporate generate sizeable extra money to pay dividends. The present dividend yield is 5.8%.
An more and more powerful buying and selling surroundings
To date, so good.
For a very long time, that enterprise mannequin was akin to a license to print cash.
Victrex has had a troublesome few years which have referred to as into query whether or not it may well maintain its previous success (and revenue margins). Submit-tax revenue final yr was 77% decrease than two years earlier than. Revenues in the identical interval slid by 12%.
As industrial functions evolve, a key threat dealing with Victrex – and it’s one I proceed to see – is whether or not demand for the types of polymers it makes will keep robust, or decline.
Indicators of a possible turnaround
So it’s comprehensible that buyers had been cheered by some parts of the corporate’s full-year outcomes, revealed final month. Sure, revenues earlier than tax had been down and pre-tax revenue was down badly.
However there was, a minimum of, quantity development.
Among the latest earnings drops might be pinned on the startup prices of latest manufacturing services in China. Now they’re operational, hopefully they will flip from a loss centre to a revenue centre for the FTSE 250 agency (although one threat I see is mental property leakage).
What in regards to the quantity story?
Greater volumes however decrease revenues sometimes level to both a change within the mixture of merchandise offered, or declining pricing energy. The corporate pinned this on trade charges and weaker efficiency in its greater margin medical division, affecting its general gross sales combine.
So, if the product combine will get again to a extra regular one (with stronger contribution from medical merchandise) and volumes proceed to develop, 2025 may see each revenues and income develop at Victrex.
If that occurs, I believe it may very well be excellent news for the Victrex share value. Having taken some income following final month’s announcement, I proceed to carry my long-term Victrex stake for now.
